Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Immunotherapy in CRC

July 10th 2019

Salvage Therapy for mCRC

July 10th 2019

New Therapy Options for BRAF-Mutated mCRC

July 10th 2019

Maintenance Therapy for mCRC

July 10th 2019

Management of Colorectal Cancer Metastases

July 10th 2019

Colon Cancer in Young Patients

July 10th 2019

TRIBE-2: FOLFOX or FOLFIRI With Bevacizumab in mCRC

July 10th 2019

Frontline Therapy for mCRC

July 10th 2019

Molecular Testing in 2019 for mCRC

July 10th 2019

Changing Paradigms for Rectal Cancer

July 10th 2019

IDEA Collaboration; Impact on Adjuvant Therapy

July 10th 2019

Adjuvant Treatment or "Watch and Wait" in Stage II CRC

July 10th 2019

Molecular Profiling in Stage II and III Colon Cancer

July 10th 2019

Adjuvant Therapy for Stage II and III Colon Cancer

July 10th 2019

Encorafenib, Binimetinib, and Cetuximab Regimen Improves Survival in BRAF+ CRC

July 6th 2019

Encorafenib, binimetinib, and cetuximab demonstrated a significant improvement in overall survival compared with cetuximab and an irinotecan-containing regimen in patients with BRAF-mutant colorectal cancer.

Published Data Back Regorafenib Dose Escalation in Colorectal Cancer

July 3rd 2019

A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.

Dr. Lieu on Investigational Immunotherapy Strategies in mCRC

July 2nd 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape

July 2nd 2019

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

TAS-102 Continues to Demonstrate Efficacy, Safety in CRC and Gastric Cancers

June 24th 2019

Howard S. Hochster, MD, provides insight into TAS-102 (trifluridine/tipiracil; Lonsurf) and highlights other important research being conducted in the colorectal cancer space.

Study Sheds Light on Incidence Patterns of Early-Onset CRC

June 24th 2019

Ana Acuna-Villaorduna, MD, provides further insight into the study that compares age and race as factors for the incidence of early-onset colorectal cancer.